CA 19-9 as a Marker of Survival and a Predictor of Metastization in Cholangiocarcinoma.

Rosa Coelho, Marco Silva, Eduardo Rodrigues-Pinto, Hélder Cardoso, Susana Lopes, Pedro Pereira, Filipe Vilas-Boas, João Santos-Antunes, José Costa-Maia, Guilherme Macedo,

GE Portuguese journal of gastroenterology, August 29, 2017

Cholangiocarcinoma is the second most frequent primitive liver malignancy and is responsible for 3% of the malignant gastrointestinal neoplasms. The aims of this study were to determine the association of serum levels of CA 19-9 at diagnosis with other clinical data and serum liver function tests and to identify possible factors that influence the survival rates during follow-up. Retrospective observational study of 89 patients with a diagnosis of cholangiocarcinoma followed at the Department of Gastroenterology during 5 years. Statistical analyses were performed using SPSS version 20.0. Patients were followed up for a median time of 127 days (IQR: 48-564), and the median age at diagnosis was 71.0 years (IQR: 62.0-77.5). The median survival rate was 14.0 months (IQR: 4.3-23.7), and the mortality rate was 79%. Patients with CA 19-9 levels ≥103 U/L had lower albumin levels and higher levels of alanine aminotransferase and γ-glutamyltransferase. CA 19-9 levels ≥103 U/L were associated with a higher probability of metastization (p = 0.001) and lower rates of treatment with curative intent (p = 0.024). In a multivariate analysis, CA 19-9 levels

Pubmed Link: 28848795

DOI: 10.1159/000452691